Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health (NASDAQ:JAGX) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025. The company's founder, president and CEO, Lisa Conte, will deliver a virtual presentation, which will be available on-demand starting at 7:00 AM Eastern on September 5, 2025.

The conference will be held in a hybrid format, offering both virtual access and in-person attendance at the Lotte New York Palace in New York City.

Jaguar Health (NASDAQ:JAGX) announced its participation in the 2025 Animal Health Summit with the goal of securing partnerships to expand Canalevia's indication from chemotherapy-induced diarrhea (CID) to general diarrhea treatment in dogs. Canalevia-CA1, their FDA conditionally approved plant-based drug, has reached 25% enrollment in its ongoing effectiveness study.

The company is in discussions with multiple potential animal health partners to achieve three key objectives: expanding U.S. indication to general diarrhea, obtaining EU approval, and maintaining U.S. availability for CID treatment. With an estimated 11 million dogs suffering from general diarrhea annually in the U.S. and a significant market in Europe's 104 million dog population, Jaguar sees substantial market potential.

Jaguar Health (NASDAQ:JAGX) announced the approval of all seven proposals at its August 2025 Annual Meeting of Stockholders. The company highlighted key clinical developments, including proof-of-concept results showing crofelemer reduced total parenteral nutrition by up to 27% in MVID patients and 12.5% in SBS-IF patients in an Abu Dhabi trial.

Following an FDA meeting, Jaguar outlined its regulatory pathway for a supplemental NDA for crofelemer in metastatic breast cancer patients. The company's strategy focuses on seeking business development partnerships for orphan indication products to secure non-dilutive funding.

Jaguar Health (NASDAQ:JAGX) subsidiary Napo Pharmaceuticals announced plans to meet with the FDA regarding crofelemer's development for treating Microvillus Inclusion Disease (MVID), an ultrarare pediatric disorder. Initial proof-of-concept results from an ongoing investigator-initiated trial in Abu Dhabi demonstrated that crofelemer reduced required total parenteral nutrition by up to 27% in the first MVID patient.

The company aims to discuss potential expedited regulatory pathways for this rare orphan indication. An abstract describing the trial results has been accepted for presentation at the NASPGHAN 2025 Annual Meeting in Chicago. Napo is currently conducting a placebo-controlled Phase 2 study of crofelemer in pediatric MVID patients across the U.S., EU, and Middle East/North Africa regions.

Jaguar Health (NASDAQ:JAGX) reported Q2 2025 financial results showing significant growth. Net revenue reached $3.0 million, marking a 35% increase from Q1 2025's $2.2 million and a 10% rise from Q2 2024. Mytesi prescription volume grew 6.5% quarter-over-quarter.

The company's financial performance showed mixed results with increased sales but wider losses. Net loss attributable to common stockholders increased to $10.4 million in Q2 2025 from $9.5 million in Q2 2024. Notable developments include positive initial proof-of-concept results from trials showing crofelemer reduced total parenteral nutrition requirements in MVID and SBS-IF patients by up to 27% and 12.5% respectively.

Jaguar Health (NASDAQ:JAGX) has scheduled two important investor events. The company will host an investor webcast on August 14, 2025, at 8:30 AM ET to discuss Q2 2025 financial results and provide corporate updates, coinciding with their 10-Q filing. Additionally, CEO Lisa Conte will present at the Emerging Growth Conference on August 20, 2025, from 2:55-3:05 PM ET to discuss near-term catalysts.

Both events will be accessible online, with the Emerging Growth Conference presentation being archived for later viewing on EmergingGrowth.com and their YouTube channel.

Jaguar Health (NASDAQ:JAGX) announced progress in its field study of Canalevia-CA1, an FDA conditionally approved prescription drug for treating chemotherapy-induced diarrhea (CID) in dogs. The company has enrolled four dogs across six veterinary oncology clinics, with more clinics potentially joining.

Jaguar is actively seeking partnerships to achieve three key objectives for Canalevia: obtain EU approval for general diarrhea treatment based on existing study data, maintain U.S. availability for CID treatment, and expand U.S. indication to include general diarrhea. The company plans to submit documentation to the European Medicines Agency (EMA) highlighting updated analysis of their completed study, potentially leading to approval across all 27 EU member countries.

The market opportunity is significant, with 104 million dogs in Europe and approximately 6 million annual cases of acute and chronic diarrhea seen by U.S. veterinarians. The drug, derived from the Croton lechleri tree, is currently available through major U.S. veterinary distributors, including Chewy.

Jaguar Health (NASDAQ:JAGX) announced that Peru's National Institute of Agrarian Innovation (INIA) has authorized an access and benefit sharing agreement for coca plant research. The agreement, signed with Psilo Scientific (a Filament Health subsidiary), supports the research efforts of Magdalena Biosciences, a joint venture between Jaguar Health and Filament Health.

The agreement focuses on two cultivated coca species - Erythroxylum coca and Erythroxylum novogranatense - and includes an Internationally Recognized Certificate of Compliance (IRCC) under the Convention on Biological Diversity. The research aims to develop novel, natural prescription medicines from coca leaves for mental health and CNS indications under FDA Botanical Guidance.

Jaguar Health (NASDAQ:JAGX) announced positive proof-of-concept results for their drug crofelemer in treating a third intestinal failure patient. The novel liquid formulation demonstrated efficacy in reducing total parenteral nutrition (TPN) requirements in a second pediatric patient with short bowel syndrome (SBS-IF).

The results build on previously reported data showing crofelemer reduced TPN requirements by up to 27% in microvillus inclusion disease (MVID) patients and up to 12.5% in SBS-IF patients. Notably, when the first two patients were taken off crofelemer after 12 weeks of treatment, their symptoms worsened, leading to prompt reinstatement of the treatment.

The company is conducting multiple studies, including two independent proof-of-concept investigator-initiated trials (IITs) and two placebo-controlled Phase 2 studies. The Phase 2 study in pediatric MVID patients is expected to complete by mid-2026. Jaguar is actively seeking business development partnerships for licensing rights to develop and commercialize their intestinal failure products, aiming to generate non-dilutive funding.

[ "Crofelemer reduced TPN requirements by up to 27% in MVID patients and 12.5% in SBS-IF patients", "Second pediatric SBS-IF patient showed similar positive response for TPN reduction", "No safety issues reported at highest protocol-approved dose", "Results may support inclusion in EMA's PRIME program and FDA's Breakthrough Therapy program", "Data could support reimbursed early patient access in EU countries" ]